Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of combined genome

A technology of renal clear cell carcinoma and genome, applied in a group of combined genomes and its application fields for evaluating the prognosis of renal clear cell carcinoma, can solve existing problems and other problems, and achieve the effect of improving survival rate

Pending Publication Date: 2020-08-25
FUDAN UNIV SHANGHAI CANCER CENT
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are problems in distinguishing high-risk metastatic ccRCC due to various genomic alterations and molecular interactions involved in this tumor metastasis, leading to potential therapeutic strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of combined genome
  • Combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of combined genome
  • Combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of combined genome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Screening of ten marker genes

[0040] 1. Raw biological microarray data analysis

[0041] Raw transcriptional microarray data from metastatic or primary ccRCC samples were screened from the GEO (http: / / www.ncbi.nlm.nih.gov / geo) database. The corresponding genes converted into probes were converted into symbols with platform-processed annotation information. Three chip datasets GSE22541, GSE47352 and GSE85258 were downloaded from the same GEO platform using Affymetrix Human Genome U133 Plus 2.0 arrays (24 primary and 44 metastatic tumor samples in GSE22541, 4 primary tumor samples in GSE47352 and 4 metastatic tumor samples, and 14 primary and 14 metastatic tumor samples in GSE85258).

[0042] 2. Normalization and clarification of DEG

[0043] Preprocessing and normalization of raw biological data is the first step in processing DNA microarrays. This process removes bias from microarray data to ensure its uniformity and integrity. Probe data were subseque...

Embodiment 2

[0063] Example 2 External Verification

[0064] From June 2009 to September 2017, 380 surgical specimens of ccRCC patients were selected from the Urology Department of Shanghai Cancer Center, Fudan University. Tissue samples including ccRCC and normal tissues were collected during surgery and are available from the FUSCC tissue bank.

[0065] 1. Real-time quantitative PCR (RT-qPCR) analysis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of the combined genome, relates to the technical field of medical biological detection, and provides novel application of the combined genome of ADAMTS9, C1S, DPYSL3, H2AFX, MINA, PLOD2, RUNX1, SLC19A1, TPX2 and TRIB3, particularly application in preparation of a ccRCC prognosis evaluation reagent or kit. The genome is derived from a molecular marker significantly correlated with a ccRCC metastasis way, and the discovery of the genome model provides a new strategy for predicting the ccRCC recurrent risk and the long-term survival condition of a patient after operation, plays important roles in judging the prognosis of the ccRCC patient, can evaluate the risk level of tumor progression or death of the patient after ccRCC operation, contributes to guiding a clinician to perform an individualized precise therapeutic strategy, can increase the postoperative survivalrate of the patient, and has important guide significance postoperative follow-up monitoring and sequential therapy management of the ccRCC patient.

Description

technical field [0001] The invention belongs to the technical field of medical biological detection, and relates to the use of a combined genome composed of ADAMTS9, C1S, DPYSL3, H2AFX, MINA, PLOD2, RUNX1, SLC19A1, TPX2 and TRIB as a marker, specifically, the combined genome is used in the preparation of renal clear cells Application in a cancer prognosis assessment reagent or kit. Background technique [0002] Renal cell carcinoma is one of the most common malignancies of the genitourinary system, accounting for about 5% of all adult males and 3% of females. According to statistics, in 2019, there were about 73,820 new cases of kidney cancer and 14,770 deaths in the United States. There are about 66,800 new kidney cancer patients in my country every year, ranking second in the incidence of urinary system tumors. Clear cell renal cell carcinoma (ccRCC) is the most common pathological type of renal cancer with a high degree of malignancy, accounting for about 70-85% of all r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12Q1/686C12N15/11
CPCC12Q1/6886C12Q1/686C12Q2600/158C12Q2600/118C12Q2545/114
Inventor 徐文浩张海梁瞿元元艾合太木江·安外尔田熙王骏施国海叶定伟
Owner FUDAN UNIV SHANGHAI CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com